亚盛医药-B（06855）今日盘中大涨8.97%，引发市场关注。截至交易时段中期，该股报价39.95港元，成交额达1.54亿港元。
本次股价上涨主要受益于公司近期研发进展的利好消息。亚盛医药宣布，公司共有五项临床前研究进展入选2025年美国癌症研究协会（AACR）年会。这些研究涉及多个重要药物，包括公司的原创1类新药奥雷巴替尼（商品名：耐立克）、Bcl-2抑制剂APG-2575、FAK/ALK/ROS1三联酪氨酸激酶抑制剂APG-2449、胚胎外胚层发育蛋白（EED）抑制剂APG-5918以及IAP拮抗剂AS03157。这一消息显示了公司在癌症治疗领域的持续创新能力，增强了投资者对公司未来发展前景的信心。
值得注意的是，本月初亚盛医药还公告称，其原创1类新药奥雷巴替尼（耐立克）获国家药品监督管理局（NMPA）药品审评中心（CDE）纳入"突破性治疗品种"名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病（ALL）患者。这是耐立克第三次获得CDE突破性治疗品种认定，进一步凸显了公司核心产品的临床价值和市场潜力，为股价上涨提供了额外支撑。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.